THC GLOBAL POISED TO ENTER NEW ZEALAND’S SURGING MEDICINAL CANNABIS MARKET

Highlights:

  • THC Global granted exclusive rights to import high quality medicinal cannabis products into New Zealand in partnership with Endoca in Europe
  • Expanded international footprint to provide accelerated access to lower cost, high quality medicinal cannabis products in the rapidly emerging NZ market
  • NZ has a simple prescription process, few competitors and strong demand for unique CBD medicinal cannabis products imported from Endoca in Europe
  • Strong interest received from over 1,000 NZ patients seeking access to Endoca’s medicinal cannabis product range
  • First medicinal cannabis sales to commence in the coming weeks
  • Over 100K potential patients in New Zealand for Endoca products

THC Global Group Limited (THC) is pleased to advise that is has secured exclusive rights to import a range of high quality medicinal cannabis products into New Zealand under its strategic partnership with Denmark-based Endoca.

THC Global will commence the importation of Endoca’s unique CBD and CBD+CBDa products from Europe via its operating subsidiary in New Zealand, THC Pharma (NZ) Limited, which has established a supply chain via New Zealand’s DATAPHARM, an online platform for prescribing and dispensing the Endoca products.

The Company has identified New Zealand as an attractive market due to favourable regulatory conditions which allow prescriptions for these CBD products to be made by doctors without Government approval as is required in Australia. This will ensure faster access by larger patient numbers and lower regulatory barriers for THC Global to generate revenue.

THC Global Chief Executive Officer, Ken Charteris commented:

“Our expansion into New Zealand represents a significant step in THC Global’s international growth strategy, targeting rapidly growing medicinal cannabis markets in the Asia Pacific and distributing Endoca’s product range. We look forward to our first orders in New Zealand in the coming weeks as we continue to expand our footprint in the global medicinal cannabis market in the near term”.

Chief Executive Officer of Endoca, Henry Vincenty, commented:

“We are excited to be able to expand our collaboration with THC following their successful launch as the exclusive distributor of Endoca products in Australia. We will continue to seek further opportunities to collaborate and expand on our partnership with THC in the near term”.

THC Global is active in establishing prescriber and pharmacy engagement programs in New Zealand and has been advised by Endoca that they have already received strong interest from over a thousand patients in New Zealand seeking their products.

With the support of New Zealand’s DATAPHARM, THC Global will commence seeking MedSafe approval from the New Zealand government for the Endoca products which, although not required to commence supply to patients, will add further credibility and attest to the safety and quality of the already GMP certified Endoca product range.

THC Global anticipates supplying Endoca’s CBD products to New Zealand patients at a substantially lower price than the only other MedSafe approved cannabis-based medication available, which costs patients $14,000 per year. This is expected to address a major barrier to patient uptake.

THC is expediting the process of obtaining import approval to begin increasing sales in New Zealand, where patient numbers for some of the main indications include 48,000 patients with Epilepsy (Source: Epilepsy NZ), 80,000 with Autism (Source: Autism NZ), 62,000 with Dementia (Source: Alzheimers NZ) 9,500 with Parkinson’s (Source: University of Otago), 4,000 with Multiple Sclerosis (Source: MS research NZ) and +96,000 with Cancer (Source: Global Health Data Exchange).

Prev   Next 

Latest Updates

  • Covid 19 and Epilepsy Update 26 March 2020
    26 March 2020

    Epilepsy New Zealand has been receiving regular information from the Ministry of Health and other agencies, often more than once a day, showing just how quickly the situation is evolving. No doubt there will be many people, including those with epilepsy, who have questions around their risk and what to do in these uncertain times. Hopefully the information below may help reassure you and where necessary, prompt you to contact your trusted health professional.

  • BPAC issues new guidelines for Lamotrigine
    26 September 2019

    BPAC issues new guidelines for Lamotrigine.

  • Petition against Pharmac's drug changes
    29 August 2019

    A petition is underway calling on Pharmac to reverse its decision on Lamotrigine.

  • Epilepsy NZ Position Statement - Lamotrigine
    28 August 2019

    We opposed this change from Lamictal to Logem from the start, and staff have advocated on behalf of people with epilepsy in discussions with Pharmac.

  • Don't Give Up by Adele Hauwai
    4 December 2017

    Adele Hauwai has shared her Living With Epilepsy story as part of the Epilepsy NZ Tell Us About It Competition. People were asked to send in their stories about epilepsy, the challenges they faced and the lessons they have learned that they would like to share with the world.

  • New ILAE Seizure Classification
    10 March 2017

    The ILAE announces the publication in Epilepsia of two new landmark classification documents, one of seizure types and one of the epilepsies.

Show Your Support

Shop Online

Epilepsy NZ has an online shop!

Or

Donate Today